Rigel Pharmaceuticals (RIGL) Raw Materials (2021 - 2025)
Rigel Pharmaceuticals has reported Raw Materials over the past 5 years, most recently at $7.0 million for Q3 2025.
- For Q3 2025, Raw Materials rose 342.96% year-over-year to $7.0 million; the TTM value through Sep 2025 reached $7.0 million, up 342.96%, while the annual FY2024 figure was $1.1 million, 76.63% down from the prior year.
- Raw Materials for Q3 2025 was $7.0 million at Rigel Pharmaceuticals, down from $9.6 million in the prior quarter.
- Over five years, Raw Materials peaked at $9.6 million in Q2 2025 and troughed at $1.1 million in Q4 2024.
- A 5-year average of $4.6 million and a median of $4.6 million in 2022 define the central range for Raw Materials.
- Biggest five-year swings in Raw Materials: plummeted 76.63% in 2024 and later surged 348.76% in 2025.
- Year by year, Raw Materials stood at $5.1 million in 2021, then decreased by 11.42% to $4.6 million in 2022, then increased by 1.19% to $4.6 million in 2023, then plummeted by 76.63% to $1.1 million in 2024, then skyrocketed by 545.31% to $7.0 million in 2025.
- Business Quant data shows Raw Materials for RIGL at $7.0 million in Q3 2025, $9.6 million in Q2 2025, and $1.1 million in Q1 2025.